CD44 and neoplasm: Xu et al. reported that CD44 knockdown via lentiviral shRNA reduced both tumour volume and proliferation rates in subcutaneous tumours of over-expressing U87MG/U251 glioma cell lines, while significantly inhibiting intracranial tumour growth and extending survival in these intracranial models [36].